Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Recommendation of “Hold” by Brokerages

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) has received a consensus recommendation of “Hold” from the thirteen brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have given a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $59.80.

Several research firms have recently issued reports on IMCR. HC Wainwright restated a “buy” rating and issued a $100.00 target price on shares of Immunocore in a report on Wednesday, February 4th. Wall Street Zen downgraded shares of Immunocore from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Needham & Company LLC raised their price objective on shares of Immunocore from $71.00 to $75.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Weiss Ratings restated a “sell (e+)” rating on shares of Immunocore in a research report on Thursday, January 22nd. Finally, Zacks Research cut Immunocore from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th.

Insider Activity at Immunocore

In related news, insider Leger Tina Amber St sold 1,000 shares of the business’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total transaction of $32,350.00. Following the completion of the transaction, the insider owned 1,119 shares in the company, valued at $36,199.65. The trade was a 47.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Bahija Jallal sold 11,474 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total value of $371,183.90. Following the completion of the sale, the chief executive officer owned 12,343 shares in the company, valued at approximately $399,296.05. The trade was a 48.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 19,137 shares of company stock worth $619,082 in the last quarter. 10.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Rockefeller Capital Management L.P. bought a new stake in Immunocore during the 4th quarter valued at about $47,000. XTX Topco Ltd bought a new position in Immunocore in the 4th quarter worth about $763,000. Voloridge Investment Management LLC purchased a new position in shares of Immunocore during the fourth quarter worth approximately $978,000. Vestal Point Capital LP purchased a new position in shares of Immunocore during the fourth quarter worth approximately $20,305,000. Finally, Virtus Investment Advisers LLC raised its stake in shares of Immunocore by 48.9% during the fourth quarter. Virtus Investment Advisers LLC now owns 18,569 shares of the company’s stock valued at $645,000 after acquiring an additional 6,097 shares in the last quarter. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Immunocore Stock Performance

NASDAQ IMCR opened at $29.29 on Tuesday. The business’s 50 day moving average price is $32.24 and its 200-day moving average price is $33.97. Immunocore has a fifty-two week low of $23.15 and a fifty-two week high of $40.71. The company has a market cap of $1.48 billion, a P/E ratio of -41.84 and a beta of 0.78. The company has a debt-to-equity ratio of 1.03, a quick ratio of 4.01 and a current ratio of 4.04.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings results on Saturday, February 14th. The company reported ($0.60) earnings per share (EPS) for the quarter. Immunocore had a negative return on equity of 9.20% and a negative net margin of 8.88%.The company had revenue of $104.48 million during the quarter. Sell-side analysts predict that Immunocore will post -0.94 earnings per share for the current year.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.